公开(公告)号：WO2023083983A1

公开(公告)日：2023-05-19

申请号：PCT/EP2022/081525

申请日：2022-11-10

Applicant: UNIVERSITE DE RENNES ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  ÉCOLE NATIONALE SUPÉRIEURE DE CHIMIE DE RENNES ,  INSTITUT NATIONAL DES SCIENCES APPLIQUÉES DE RENNES ,  NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY

Inventor： BENVEGNU, Thierry ,  VIVES, Thomas ,  HICGUET, Matthieu ,  SIMON, Sébastien ,  SJÖBLOM, Johan

IPC: C07C31/27 ,  C07C55/26 ,  C07C69/60 ,  C07D249/04 ,  A61K47/14 ,  A61K47/50 ,  A61K9/127 ,  A61P1/00 ,  C07C219/10 ,  C07C69/608

Abstract: The present invention thus provides a novel family of liposomal compositions (nanocarriers), hereinafter referred to as Tetra-Acidosomes, comprising natural tetrameric acid (TA) lipids and/or novel chemically functionalized tetrameric acid (CFTA) lipids, for drug delivery applications.

公开(公告)号：WO2023060253A1

公开(公告)日：2023-04-13

申请号：PCT/US2022/077784

申请日：2022-10-07

Applicant: REVOLUTION MEDICINES, INC.

Inventor： BUCKL, Andreas ,  BURNETT, G., Leslie ,  CREGG, James ,  EDWARDS, Anne, V. ,  GILL, Adrian, L. ,  KNOX, John, E. ,  KOLTUN, Elena, S. ,  LIU, Yang ,  SEMKO, Christopher

IPC: C07D519/00 ,  A61P35/00 ,  A61K47/50 ,  A61K31/501

Abstract: The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

公开(公告)号：WO2023010200A1

公开(公告)日：2023-02-09

申请号：PCT/CA2022/000035

申请日：2022-08-05

Applicant: UNIVERSITY OF WINDSOR

Inventor： VUKOTIC, Vedran Nicholas ,  MURPHY, Jennifer Nicole ,  KOBTI, Joy-Lynn ,  DAO, Michelle

IPC: A61K47/50 ,  A61K47/54 ,  A61K47/56 ,  C07C237/06 ,  C07D213/80 ,  C07D233/61

Abstract: In a preferred embodiment, there is provided a pharmaceutical coordination composition having a plurality of central atoms or ions, a multitopic ligand and one or more pharmaceutical compounds coordinated to at least one of the plurality of the central atoms or ions, wherein the multitopic ligand is coordinated to at least two of the plurality of central atoms or ions.

公开(公告)号：WO2022266340A1

公开(公告)日：2022-12-22

申请号：PCT/US2022/033819

申请日：2022-06-16

Applicant: VACCITECH NORTH AMERICA, INC. ,  THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

Inventor： LYNN, Geoffrey, M. ,  ZHU, Yaling ,  NICHOLS, Sarah, R. ,  REN, Qiuyin ,  ISHIZUKA, Andrew, S.

IPC: A61K47/10 ,  A61K47/34 ,  A61K47/44 ,  A61K47/22 ,  A61K47/50 ,  A61K47/56 ,  A61K47/69 ,  A61K9/107 ,  A61K9/50 ,  A61K9/51 ,  A61P35/00 ,  B82Y5/00 ,  C08G69/00 ,  C08G81/00 ,  C08G83/00

Abstract: The present disclosure relates to a composition comprising a first amphiphile and optionally a second amphiphile each having the formula S-[B]-[U]-H-[D] and at least one dmg molecule is noncovalently associated with or covalently bonded directly or via a suitable linker XI to the first amphiphile and/or to the optional second amphiphile. The composition is useful in treating a cancer, an infectious disease or an inflammatory disease.

公开(公告)号：WO2022251665A1

公开(公告)日：2022-12-01

申请号：PCT/US2022/031383

申请日：2022-05-27

Applicant: RENAGADE THERAPEUTICS MANAGEMENT INC. ,  JAYARAMAN, Muthusamy

Inventor： LAWLOR, Ciaran ,  GOODMAN, Brian

IPC: A61K47/50 ,  A61K9/127 ,  A61K31/33 ,  A61K47/54 ,  C07C229/00 ,  A61K31/00

Abstract: The present disclosure provides pharmaceutical compositions comprising lipid nanoparticles capable of delivering polynucleotide payloads to target non-liver organs.

公开(公告)号：WO2022246576A1

公开(公告)日：2022-12-01

申请号：PCT/CA2022/050864

申请日：2022-05-27

Applicant: ZYMEWORKS INC.

Inventor： PETERSEN, Mark Edmund ,  BRANT, Michael G. ,  COLOMBO, Raffaele ,  RICH, James R. ,  LASALLE, Manuel Michel Auguste ,  BARNSCHER, Stuart Daniel ,  DAS, Samir

IPC: C07D491/22 ,  A61K31/541 ,  A61K31/4745 ,  A61K31/5377 ,  A61K47/50 ,  A61K47/68 ,  A61P31/12 ,  A61P35/00 ,  A61P37/06 ,  C07D519/00 ,  C07K16/00 ,  C07K16/08 ,  C07K16/18 ,  C07K16/30

Abstract: Camptothecin analogues of Formula (I) and conjugates comprising the camptothecin analogues are described. The camptothecin analogues and conjugates may be used as therapeutic agents, particularly in the treatment of cancer, an autoimmune disease or a viral infection.

公开(公告)号：WO2022234536A1

公开(公告)日：2022-11-10

申请号：PCT/IB2022/054229

申请日：2022-05-06

Applicant: ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECHNOLOGIES & THERAPIES (A4TEC) - ASSOCIAÇÃO

Inventor： DA COSTA MACHADO FERREIRA, Helena Susana ,  GONÇALVES DOS REIS, Rui Luís ,  MELEIRO ALVES DAS NEVES, Nuno João

IPC: A61K38/00 ,  A61K31/728 ,  A61K38/07 ,  A61K38/08 ,  A61K38/10 ,  A61K45/06 ,  A61K47/50 ,  A61K9/0019 ,  A61K9/06 ,  A61K9/127 ,  A61P1/00 ,  A61P35/00

Abstract: The present disclosure relates to a hydrogel composition for use in the treatment or therapy of a solid tumor comprising a hyaluronic acid polymer; one or more peptide sequence, wherein the peptide sequence is an inhibitor of extracellular matrix components, namely fibronectin, tenascin C, vitronectin, laminin or collagen; and liposomes, wherein the liposomes are arranged to physically crosslink the hyaluronic acid polymer; or hyaluronic acid and at least one peptide sequence. The disclosure also relates to a pharmaceutical composition for use in the treatment or therapy of a solid tumor, particularly gliomas and preferably glioblastoma, comprising a therapeutically effective amount of the disclosed hydrogel and a pharmaceutically acceptable excipient/carrier.

公开(公告)号：WO2022187346A1

公开(公告)日：2022-09-09

申请号：PCT/US2022/018498

申请日：2022-03-02

Applicant: GEORGIA TECH RESEARCH CORPORATION

Inventor： XIE, Xing ,  CHEN, Wensi

IPC: A61K47/30 ,  A61K47/50

Abstract: Disclosed herein are methods of transport using a hydrogel material, the method comprising: providing a hydrogel material comprising a polymer scaffold comprising a plurality of pores, the polymer scaffold having an affinity to an active component; mixing the hydrogel material with liquid to cause the polymer scaffold to swell to a pore size, the pore size configured to allow the active component to pass therethrough; binding the active component with the hydrogel material; and exposing the hydrogel material to one or more stimuli, thereby causing the hydrogel material to release the active component. Also disclosed herein are hydrogel materials used for the same.

公开(公告)号：WO2022182743A1

公开(公告)日：2022-09-01

申请号：PCT/US2022/017499

申请日：2022-02-23

Applicant: CHILDREN'S MEDICAL CENTER CORPORATION

Inventor： GUO, Peng ,  HUANG, Jing ,  MOSES, Marsha, A.

IPC: A61K39/395 ,  A61K47/50 ,  A61K47/68 ,  A61P35/00 ,  C07K16/30

Abstract: The disclosure provides compositions comprising intercellular adhesion molecule 1 (ICAM1) antibody and methods for using the same for therapeutic applications, for example, treating triple negative breast cancer (TNBC) and predicting drug response.

公开(公告)号：WO2022177981A2

公开(公告)日：2022-08-25

申请号：PCT/US2022/016584

申请日：2022-02-16

Applicant: THE JOHNS HOPKINS UNIVERSITY

Inventor： MAO, Hai-Quan ,  HU, Yizong ,  ZHU, Yining

IPC: A61K47/69 ,  A61K9/51 ,  A61K47/50 ,  B82Y5/00 ,  B01F25/10 ,  B01F25/25 ,  A61K9/5146 ,  A61K9/5153 ,  A61K9/5161 ,  A61K9/5192

Abstract: A scalable method for producing DNA/polycation particles having an optimal, defined particle size with multiple virus assembly plasmids for efficient transfection of viral production cells in suspension cultures. The presently disclosed DNA/polycation particles yield superior and reproducible transfection activity and shelf stability in the suspension form and can be used as an off-the-shelf product. The presently disclosed DNA/polycation particle formulation can potentially simplify and streamline the viral manufacturing process and improve production quality and consistency.